Completed PHASE3 INTERVENTIONAL 2-arm NCT05507645

ProUrokinase for Mild Ischemic Cerebrovascular Events (PUMICE) (PUMICE)

Recombinant Human Prourokinase（rhPro-UK）for Injection Versus Standard Medical Treatment for Acute Mild Ischemic Stroke (NIHSS≤5) Within 4.5 Hours After Symptom Onset

Sponsor: Beijing Tiantan Hospital

Conditions Ischemic Stroke Mild Thrombosis

Interventions Recombinant Human Prourokinase for Injection (rhPro-UK) standard medical treatment

Updated 7 times since 2022 Last updated: Aug 31, 2024 Started: Nov 15, 2022 Primary completion: Mar 26, 2024 Completion: Jun 17, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05507645, this PHASE3 trial focuses on Ischemic Stroke and Mild and remains completed. Sponsored by Beijing Tiantan Hospital, it has been updated 7 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Oct 2024 — Sep 2025 [monthly]

Completed PHASE3
Sep 2024 — Oct 2024 [monthly]

Completed PHASE3
Aug 2024 — Sep 2024 [monthly]

Completed PHASE3

Status: Recruiting → Completed
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE3

▶ Show 2 earlier versions

Nov 2022 — Jul 2024 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Sep 2022 — Nov 2022 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Tiantan Hospital

Data source: Beijing Tiantan Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anshan, China , Baoding, China , Baotou, China , Beijing, China , Changsha, China , Chengde, China , Chongqing, China , Dalian, China , Dezhou, China , Dingxi, China and 46 more locations